Correlation between expression of excision repair cross-complementing 1 and cisplatin sensitivity in non-small cell lung cancer

National Medical Journal of China

Volumn 90, Issue 30, 2010, Pages 2115-2118

  Han, Xing Peng ^a   Zhang, Xun ^a  

^a TIANJIN CHEST HOSPITAL   (China)

Author keywords

Cisplatin; Excision repair cross complementing 1; Non small cell lung cancer

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ARTICLE; CANCER STAGING; CANCER SURGERY; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; TREATMENT RESPONSE; AGED; DRUG RESISTANCE; FEMALE; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 84871423978     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.30.008     Document Type: Article

References (9)

1. Campelo R G, Curbera G A, Aparicio L M, et al. Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. Expert Opin Pharmacother, 2005, 6:2015-2026.
2. Lord R V, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 2002, 8:2286-2291.
3. Altaha R, Liang X, Yu J J, et al. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med, 2004, 14:959-970.
4. Garcia-Campelo R, Alonso-Curbera G, Anton Aparicio L M, et al. Phaemacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. Expert Opin Pharmacother, 2005, 6:2015-2026.
5. Bernstein C, Bernstein H, Payne C M, et al. DNA repair/proapoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res, 2002, 511: 145-178.
6. Li J, Li Z N, Yu L C, et al. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer, 2009, 64:121-126.
7. Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer, 2010, 67:101-107.
8. Fujii T, Toyooka S, Ichimura K, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer, 2008, 59:377-384.
9. Lee K H, Min H S, Han S W, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer, 2008, 60:401-407.